Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies

Oded Shamriz; Yuval Tal; Aviv Talmon; Amit Nahum

doi:10.3389/fimmu.2020.593289

Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies

Oded Shamriz, Yuval Tal, Aviv Talmon, Amit Nahum

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Children with chronic mucocutaneous candidiasis (CMC) experience recurrent infections with Candida spp. Moreover, immune dysregulation in the early life of these patients induces various autoimmune diseases and affects normal growth and development. The adaptive and innate immune system components play a significant role in anti-fungal response. This response is mediated through IL-17 production by T helper cells. Inborn errors in IL-17-mediated pathways or Candida spp. sensing molecules are known to cause CMC. In this review, we describe underlying immune mechanisms of monogenic primary immune deficiency disorders known to cause CMC. We will explore insights into current management of these patients and novel available therapies.

Original language	English
Article number	593289
Journal	Frontiers in Immunology
Volume	11
DOIs	https://doi.org/10.3389/fimmu.2020.593289
State	Published - 16 Oct 2020
Externally published	Yes

Keywords

CMC
autoimmunity
chronic mucocutaneous candidiasis
immune dysregulation
primary immune deficiency

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.3389/fimmu.2020.593289

Cite this

@article{f0b7d46d08bb423693febdb109597dfe,

title = "Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies",

abstract = "Children with chronic mucocutaneous candidiasis (CMC) experience recurrent infections with Candida spp. Moreover, immune dysregulation in the early life of these patients induces various autoimmune diseases and affects normal growth and development. The adaptive and innate immune system components play a significant role in anti-fungal response. This response is mediated through IL-17 production by T helper cells. Inborn errors in IL-17-mediated pathways or Candida spp. sensing molecules are known to cause CMC. In this review, we describe underlying immune mechanisms of monogenic primary immune deficiency disorders known to cause CMC. We will explore insights into current management of these patients and novel available therapies.",

keywords = "CMC, autoimmunity, chronic mucocutaneous candidiasis, immune dysregulation, primary immune deficiency",

author = "Oded Shamriz and Yuval Tal and Aviv Talmon and Amit Nahum",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2020 Shamriz, Tal, Talmon and Nahum.",

year = "2020",

month = oct,

day = "16",

doi = "10.3389/fimmu.2020.593289",

language = "English",

volume = "11",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Chronic Mucocutaneous Candidiasis in Early Life

T2 - Insights Into Immune Mechanisms and Novel Targeted Therapies

AU - Shamriz, Oded

AU - Tal, Yuval

AU - Talmon, Aviv

AU - Nahum, Amit

PY - 2020/10/16

Y1 - 2020/10/16

N2 - Children with chronic mucocutaneous candidiasis (CMC) experience recurrent infections with Candida spp. Moreover, immune dysregulation in the early life of these patients induces various autoimmune diseases and affects normal growth and development. The adaptive and innate immune system components play a significant role in anti-fungal response. This response is mediated through IL-17 production by T helper cells. Inborn errors in IL-17-mediated pathways or Candida spp. sensing molecules are known to cause CMC. In this review, we describe underlying immune mechanisms of monogenic primary immune deficiency disorders known to cause CMC. We will explore insights into current management of these patients and novel available therapies.

AB - Children with chronic mucocutaneous candidiasis (CMC) experience recurrent infections with Candida spp. Moreover, immune dysregulation in the early life of these patients induces various autoimmune diseases and affects normal growth and development. The adaptive and innate immune system components play a significant role in anti-fungal response. This response is mediated through IL-17 production by T helper cells. Inborn errors in IL-17-mediated pathways or Candida spp. sensing molecules are known to cause CMC. In this review, we describe underlying immune mechanisms of monogenic primary immune deficiency disorders known to cause CMC. We will explore insights into current management of these patients and novel available therapies.

KW - CMC

KW - autoimmunity

KW - chronic mucocutaneous candidiasis

KW - immune dysregulation

KW - primary immune deficiency

UR - http://www.scopus.com/inward/record.url?scp=85094667102&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2020.593289

DO - 10.3389/fimmu.2020.593289

M3 - Review article

C2 - 33178226

AN - SCOPUS:85094667102

SN - 1664-3224

VL - 11

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 593289

ER -

Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this